Definium Therapeutics (NASDAQ:DFTX) Releases Earnings Results, Misses Expectations By $0.89 EPS

Definium Therapeutics (NASDAQ:DFTX) released its quarterly earnings results on Thursday. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• EMERGE phase III results were highly positive, with DT120 ODT producing an 8.1-point placebo-adjusted MADRS improvement in major depressive disorder at week six, statistically significant benefits from week one through week 12, and what management described as a favorable tolerability profile.
• Definium expects to report topline results from its VOYAGE phase III generalized anxiety disorder study during the week of August 10, 2026, followed by PANORAMA results in September; both trials completed enrollment and were estimated to have more than 99% power to detect the targeted treatment effect.
• The company raised approximately $758 million in net proceeds from an upsized public offering and ended the quarter with about $1.1 billion in cash, cash equivalents, and investments, which management believes can fund operations into 2030.
• Definium is expanding its commercial infrastructure ahead of a potential DT120 launch, including market access, sales, patient support, payer engagement, and clinician-awareness initiatives for GAD and MDD.
• Quarterly net loss increased to $159 million from $42.7 million a year earlier, while R&D and G&A expenses rose substantially as the company invested in clinical programs, personnel, and commercialization; an $86.2 million non-cash warrant valuation expense was a major contributor to the loss.

Definium Therapeutics Price Performance

Shares of DFTX remained flat at $46.14 during midday trading on Friday. The stock had a trading volume of 2,546,522 shares, compared to its average volume of 1,708,891. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. Definium Therapeutics has a one year low of $8.70 and a one year high of $49.70. The company has a market cap of $4.60 billion, a PE ratio of -13.45 and a beta of 2.23. The company’s 50 day moving average price is $37.89 and its two-hundred day moving average price is $25.87.

Insiders Place Their Bets

In related news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider owned 320,571 shares of the company’s stock, valued at $14,435,312.13. This represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at approximately $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 in the last ninety days. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DFTX. Bank of New York Mellon Corp lifted its stake in Definium Therapeutics by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after buying an additional 24,349 shares during the period. Flagship Harbor Advisors LLC bought a new position in shares of Definium Therapeutics in the fourth quarter valued at $117,000. Caxton Associates LLP bought a new position in shares of Definium Therapeutics in the third quarter valued at $126,000. Sender Co & Partners Inc. acquired a new position in shares of Definium Therapeutics during the third quarter valued at about $305,000. Finally, Scientech Research LLC acquired a new position in shares of Definium Therapeutics during the third quarter valued at about $286,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday. Leerink Partners set a $52.00 target price on shares of Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Stifel Nicolaus lifted their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, Citigroup reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Definium Therapeutics has a consensus rating of “Buy” and an average price target of $55.00.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.